Table 2 Baseline HPV-16 E6/E7 median OD1 ratios2 and ranges by risk factors, and histopathologic characteristics
Characteristics | HPV-16 E6 | HPV-16 E7 | HPV-16 E6 and/or E7 | |||
|---|---|---|---|---|---|---|
Positive (n = 22) | Positive (n = 20) | Positive (n = 26) | ||||
n (%) | Median (Range) | n (%) | Median (Range) | n (%) | Median (Range) | |
Gender | ||||||
Male | 15 (22.4) | 5.2 (1.8-11.3) | 15 (22.4) | 5.5 (1.3-37.2) | 17 (25.4) | 5.9 (1.3-37.2) |
Female | 7 (16.7) | 4.7 (1.2-5.7) | 5 (11.9) | 2.1 (1.01-14.7) | 9 (21.4) | 4.7 (1.2-14.7) |
Age Group | ||||||
≤ 55 years | 14 (31.8) | 5.3 (1.2-10.8) | 12 (27.3) | 4.9 (1.01-37.2) | 15 (34.1) | 5.5 (4.2-37.2) |
> 55 years | 8 (12.3) | 5.0 (1.8-11.3) | 8 (12.3) | 5.7 (1.3-14.7) | 11 (16.9) | 5.8 (1.2-14.7) |
Number of Partners | ||||||
0-2 | 7 (16.7) | 4.7 (1.2-7.3) | 6 (14.3) | 1.8 (1.01-37.2) | 9 (21.4) | 4.6 (1.2-37.2) |
3-9 | 5 (17.9) | 5.9 (1.8-9.0) | 4 (14.3) | 4.9 (3.8-11.0) | 5 (17.9) | 7.3 (5.2-11.0) |
≥ 10 | 9 (29.0) | 5.0 (2.5-11.3) | 8 (25.8) | 5.5 (1.5-9.3) | 10 (32.3) | 5.6 (4.2-11.3) |
Pack years | ||||||
Never | 6 (20.7) | 5.0 (1.2-9.0) | 4 (13.8) | 5.0 (3.8-9.3) | 6 (20.7) | 5.6 (1.2-9.3) |
≤ 30 | 12 (46.2) | 5.1 (2.5-10.8) | 10 (38.5) | 5.5 (1.01-37.2) | 12 (46.2) | 5.7 (4.3-37.2) |
> 30 | 4 (7.4) | 5.3 (1.8-11.3) | 6 (11.1) | 6.8 (1.3-14.7) | 8 (14.8) | 5.3 (1.3-14.7) |
Drinks per Week | ||||||
Never | 6 (17.6) | 5.1 (1.2-7.8) | 5 (14.7) | 6.1 (1.3-9.3) | 7 (20.6) | 5.9 (1.2-9.3) |
≤ 21 | 10 (22.7) | 5.3 (2.5-10.8) | 9 (20.5) | 4.3 (1.01-37.2) | 12 (27.3) | 5.6 (2.1-37.2) |
> 21 | 6 (19.4) | 4.7 (1.8-11.3) | 6 (19.4) | 5.0 (1.5-11.0) | 7 (22.6) | 5.2 (4.2-11.3) |
Tumor Site | ||||||
Oropharynx | 20 (74.1) | 5.1 (1.8-11.3) | 16 (59.3) | 5.7 (1.01-37.2) | 20 (74.1) | 5.9 (4.3-37.2) |
Oral Cavity | 2 (2.7) | 2.6 (1.2-4.1)3 | 2 (2.7) | 9.5 (4.2-14.7)3 | 4 (5.5) | 4.2 (1.2-14.7) |
Larynx\hypopharynx | 0 (0.0) | - | 2 (22.2) | 1.7 (1.3-2.1)3 | 2 (22.2) | 1.7 (1.3-2.1)3 |
Stage | ||||||
I/II | 2 (5.0) | 2.6 (1.2-4.1)3 | 1 (2.5) | 1.3 (1.3-1.3)3 | 3 (7.5) | 1.3 (1.2-4.1)* |
III/IV | 20 (29.0) | 5.1 (1.8-11.3) | 19 (27.5) | 5.5 (1.01-37.2) | 23 (33.3) | 5.8 (2.1-37.2)* |
Tumor Size | ||||||
T0-T2 | 18 (28.6) | 4.9 (1.2-11.3)* | 13 (20.6) | 5.5 (1.01-37.2) | 19 (30.2) | 5.5 (1.2-37.2) |
T3-T4 | 4 (9.1) | 6.8 (5.2-10.8)* | 7 (15.9) | 5.5 (2.1-14.7) | 7 (15.9) | 5.9 (2.1-14.7) |
Grade | ||||||
Poor/Undifferentiated | 11 (44.0) | 5.7 (4.2-11.3) | 9 (36) | 5.8 (1.01-37.2) | 12 (48.0) | 5.9 (1.3-37.2) |
Well/Moderate | 11 (13.1) | 5.0 (1.2-10.8) | 11 (13.1) | 5.5 (1.6-14.7) | 14 (16.7) | 5.2 (1.2-14.7) |
Nodal Involvement | ||||||
Yes | 20 (39.2) | 5.1 (1.8-11.3) | 17 (33.3) | 5.5 (1.01-37.2) | 21 (41.2) | 5.8 (4.2-37.2)* |
No | 2 (3.5) | 2.6 (1.2-4.1)3 | 3 (5.2) | 2.1 (1.3-14.7) | 5 (8.6) | 2.1 (1.2-14.7)* |
HPV DNA | ||||||
High-Risk | 20 (66.7) | 5.0 (1.2-11.3) | 16 (53.3) | 5.7 (1.01-37.2) | 21 (70.0) | 5.7 (1.2-37.2) |
Negative | 2 (2.5) | 7.1 (5.2-9.0) | 4 (5.1) | 3.0 (1.3-14.7) | 5 (6.3) | 5.2 (1.3-14.7) |